Risk of second primary malignancies in survivors of pancreatic neuroendocrine neoplasms from 2000 to 2018
Journal of Gastroenterology and Hepatology · 2023
DOI: 10.1111/jgh.16201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2023. Verfasst von Zhen Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary Surgery, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Neoplasms, Second Primary, Neuroendocrine Tumors, Pancreatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Background and Aim As a result of improved survival, cancer survivors continue to remain at risk of developing second primary malignancies (SPMs). However, the association between first primary pancreatic neuroendocrine neoplasms (PanNENs) and SPMs has not been thoroughly investigated.
Methods
Using the Surveillance, Epidemiology, and End Results‐18 database, patients histologically diagnosed with PanNENs as their first malignancy between 2000 and 2018 were identified. Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) and excess absolute risks per 10 000 person‐years of SPMs were calculated to estimate the risk of being diagnosed with subsequent cancers compared with the general population.
Results
A total of 489 (5.7%) PanNENs survivors developed an SPM during the follow up, with a median latency between first and second cancer diagnoses of 32.0 months. The overall SIR of SPMs was 1.30 (95% CI: 1.19, 1.42) and the excess absolute risk was 35.67 cases per 10 000 person‐years in comparison with the general population. Age 25–64 years at PanNENs diagnosis was associated with statistically higher risks for SPMs of all cancers combined. Latency stratification was significant for elevated SPMs risk between 2–23 and 84+ months after diagnosis. White patients were found to have a significantly increased incidence of SPMs (SIR: 1.23, 95% CI: 1.11, 1.35), mainly owing to the higher risk of stomach, small intestine, pancreas, kidney and renal pelvis, and thyroid cancers.
Conclusion
Pancreatic neuroendocrine neoplasms survivors experience a significant increase in the burden of SPMs compared with the reference population. The heightened relative risk calls for careful long‐term scrutiny as part of survivorship care plans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatopancreatobiliary Surgery, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
- Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China.
- Department of Infectious Diseases, Qingdao Women and Children's Hospital, Qingdao University, Qingdao, China.
ORCID-Profile: Zhen Yang
Förderung
- Natural Science Foundation of Shandong Province
Zitieren
APA
Yang, Z., Liu, L., Leng, K., & Shi, G. (2023). Risk of second primary malignancies in survivors of pancreatic neuroendocrine neoplasms from 2000 to 2018. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16201
Vancouver
Yang Z, Liu L, Leng K, Shi G. Risk of second primary malignancies in survivors of pancreatic neuroendocrine neoplasms from 2000 to 2018. Journal of Gastroenterology and Hepatology. 2023. doi:10.1111/jgh.16201
BibTeX
@article{Yang2023,
author = {Yang, Zhen and Liu, Lianshuang and Leng, Kaiming and Shi, Guangjun},
title = {Risk of second primary malignancies in survivors of pancreatic neuroendocrine neoplasms from 2000 to 2018},
journal = {Journal of Gastroenterology and Hepatology},
year = {2023},
doi = {10.1111/jgh.16201}
}
EUVIMED